Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102501 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia
A Phase 3 study, sponsored by Biojiva.
- Completed
- Registry status
- Phase 3
- Development phase
- 65
- Enrollment target
NCT04102501 is a Phase 3 study that has completed, run by Biojiva. The registered enrollment target is 65 participants.
The verdict
NCT04102501, a Phase 3 study, has completed, sponsored by Biojiva.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 65 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the Efficacy, Long Term Safety and Tolerability of RT001 in subjects with Friedreich's Ataxia
Interventions
- DRUG Placebo
- DRUG RT001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2021-08-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04102501
The ClinicalTrials.gov registry entry for NCT04102501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biojiva, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04102501 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04102501 about?
NCT04102501 is a clinical study titled "A Study to Assess Efficacy, Long Term Safety and Tolerability of RT001 in Subjects With Friedreich's Ataxia". The purpose of this study is to assess the Efficacy, Long Term Safety and Tolerability of RT001 in subjects with Friedreich's Ataxia
What is the current status of trial NCT04102501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 65 participants. The study started on 2019-10-30. Estimated completion is 2021-08-23.
What interventions are being tested in trial NCT04102501?
The interventions under investigation include: Placebo (DRUG), RT001 (DRUG).
Who is sponsoring clinical trial NCT04102501?
This trial is sponsored by Biojiva, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.